A carregar...
Benzimidazole-based FabI inhibitors: A promising novel scaffold for anti-staphylococcal drug development
The enoyl-ACP reductase (FabI) enzyme is a well validated target for anti-staphylococcal drug discovery and development. With the goal of finding alternate therapeutics for drug resistant strains of S. aureus, such as methicillin resistant S. aureus (MRSA), our previously published series of benzimi...
Na minha lista:
| Publicado no: | ACS Infect Dis |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5659837/ https://ncbi.nlm.nih.gov/pubmed/27756129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsinfecdis.6b00123 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|